The assumption that inflammatory bowel disease is confined to the gut is increasingly difficult to sustain. A growing body of evidence now implicates IBD in neurological outcomes — and for the roughly 8 million people living with Crohn's disease or ulcerative colitis in Western nations, understanding whether their condition accelerates cognitive aging carries profound implications for disease management and long-term care planning.
This PRISMA-compliant systematic review, published in the Journal of Crohn's & Colitis, synthesized findings from 66 studies spanning population-level epidemiology, human genetics, and preclinical models. The review encompassed 31 observational population studies, 13 genetic investigations — including Mendelian randomization and genome-wide association studies (GWAS) — and 22 preclinical experiments. The cognitive domains assessed included memory, attention, and executive function. Among the mechanistic candidates identified, chronic systemic inflammation, gut-brain axis dysregulation, and psychological comorbidities such as anxiety and depression emerged as plausible contributors to cognitive deficits. Importantly, the review also examined whether existing IBD treatments — including biologics and immunomodulators — may meaningfully influence cognitive trajectories, either by dampening neuroinflammatory pathways or through independent neurological effects.
What makes this review particularly notable is its inclusion of Mendelian randomization studies, which can partially address reverse causation and confounding that plague observational data — a significant methodological strength missing from earlier IBD-cognition literature. That said, the authors acknowledge that findings across study types remain controversial, a signal that effect sizes are likely modest and highly context-dependent. The preclinical models, while mechanistically illuminating, use murine colitis paradigms that imperfectly replicate human IBD heterogeneity. Furthermore, psychological comorbidity — depression and anxiety are disproportionately prevalent in IBD — is a potent independent driver of cognitive impairment, making clean attribution difficult. This review is best interpreted as confirmatory of a plausible association rather than proof of causality. For clinicians, it raises a reasonable case for incorporating cognitive screening into IBD follow-up, particularly in older patients with long disease duration and elevated inflammatory burden.